Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05868733 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 2026 to Dec 2026v3 Show 5 more changesShow less
    • Study completion date: Feb 2027 to Apr 2027
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Site contacts updated at 1 of 3 sites
    • Study description shortened, about 4 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Mar 6, 2024
    • Study sites: 0 to 3
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
Trial Details
NCT Number NCT05868733
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: Coalition for Epidemic Preparedness Innovations
Conditions
(from sponsor)		 Lassa Fever
Related terms Lassa Fever
Enrollment 612 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov